Drug Interactions between toremifene and tranexamic acid
This report displays the potential drug interactions for the following 2 drugs:
- toremifene
- tranexamic acid
Interactions between your drugs
tranexamic acid toremifene
Applies to: tranexamic acid and toremifene
MONITOR CLOSELY: There are no clinical data on the use of tranexamic acid in combination with estrogens or selective estrogen receptor modulators. Because tranexamic acid is an antifibrinolytic agent, concomitant use may further exacerbate the risk of thrombotic events, including venous thromboembolism as well as arterial thromboses such as stroke and myocardial infarction, associated with estrogenic therapy. During postmarketing use of tranexamic acid for the treatment of cyclic heavy menstrual bleeding, there have been reports of venous and arterial thrombotic events in women who used tranexamic acid during treatment with combination hormonal contraceptives.
MANAGEMENT: Caution and close monitoring for thromboembolic adverse effects are recommended if tranexamic acid is prescribed with estrogens or selective estrogen receptor modulators. Patients should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.
References (6)
- (2001) "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn
- van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR (2009) "The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study." BMJ, 339, b2921
- Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) "Hormonal contraception and risk of venous thromboembolism: national follow-up study." BMJ, 339, b2890
- (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc
- Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM (2003) "Estrogens, progestogens and thrombosis." J Thromb Haemost, 1, p. 1371-80
- Gomes MP, Deitcher SR (2004) "Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review." Arch Intern Med, 164, p. 1965-76
Drug and food interactions
toremifene food
Applies to: toremifene
GENERALLY AVOID: Coadministration with grapefruit juice may theoretically increase the plasma concentrations of toremifene. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by certain compounds present in grapefruit. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
GENERALLY AVOID: Due to their estrogenic effect, isoflavones present in soy such as genistein and daidzein may stimulate breast tumor growth and antagonize the antiproliferative action of toremifene. Supportive data are derived primarily from in vitro and animal studies. In vitro, low concentrations of these phytoestrogens have been found to promote DNA synthesis and reverse the inhibitory effect of tamoxifen on oestrogen-dependent breast cancer cell proliferation. In contrast, high concentrations of genistein greater than 10 microM/L have been found to enhance tamoxifen effects by inhibiting breast cancer cell growth. It is not known if these high concentrations are normally achieved in humans. Plasma concentrations below 4 microM/L have been observed in healthy volunteers given a soy diet for one month or large single doses of genistein. These concentrations are comparable to the low plasma concentrations associated with tumor stimulation reported in animals. In a study of 155 female breast cancer survivors with substantially bothersome hot flashes, a product containing 50 mg of soy isoflavones (40% to 45% genistein; 40% to 45% daidzein; 10% to 20% glycitein) taken three times a day was found to be no more effective than placebo in reducing hot flashes. No toxicity or recurrence of breast cancer was reported during the 9-week study period.
MANAGEMENT: Until more information is available, patients treated with toremifene should consider avoiding the consumption of grapefruit juice and soy-containing products. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.
References (2)
- (2001) "Product Information. Fareston (toremifene)." Schering Corporation
- Therapeutic Research Faculty (2008) Natural Medicines Comprehensive Database. http://www.naturaldatabase.com
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.